Skip to content

Comparison of Th1 Cytokine Levels Between Type 1 and Type 2 Diabetes

Comparison of Th1 Cytokine Levels Between Type 1 and Type 2 Diabetes

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02860611
Enrollment
180
Registered
2016-08-09
Start date
2013-02-28
Completion date
2016-06-30
Last updated
2016-08-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 1 Diabetes, Type 2 Diabetes

Keywords

Type 1 diabetes, Type 2 diabetes, T helper 1 cytokines

Brief summary

Recent reports show increased prevalence of obesity in patients with type 1 diabetes (T1DP)s while some studies stated that patients with type 2 diabetes (T2DPs) have islet cell auto-antibodies. These results raise the question of a common pathway in T1DM and T2DM via an association with T helper cells. In this study investigators aimed to investigate the difference between T helper 1 (Th1) cytokines levels in T1DPs, T2DPs and healthy subjects. The study included 114 T1DPs on insulin treatment, 35 newly diagnosed T2DPs who had not used oral antidiabetics but insulin before and 31 healthy subjects (CG). Serum interferon gamma (IFN-γ), interleukin-2 (IL-2) and tumor necrosis factor alpha (TNF-α) levels were measured using ELISA method. Serum levels of those cytokines in T1DPs were compared with those in T2DPs and controls.

Interventions

None listed

Sponsors

Istanbul Medeniyet University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
Yes

Inclusion criteria

* Being \>18 years old * Giving consent to participate

Exclusion criteria

* Acute and chronic inflammatory diseases * significant concomitant disease likely to interfere with glucose metabolism, * malignancies, * hemoglobinopathies, * In addition, glucose intolerance (fasting glucose level and that after glucose load) and HbA1C ≥ 5.7 % were also used

Design outcomes

Primary

MeasureTime frame
Difference in T helper cytokines between groups6 months

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026